AstraZeneca positioned for success in key breast cancer drug trials, says leading US investment bank
JP Morgan analysts see AstraZeneca PLC (LSE:AZN) in a strong position to dominate the market for a new breast cancer treatment if upcoming clinical trial results are positive. Its drug candidate, c...
AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline
AZN inks an agreement with CSPC Pharmaceutical to develop a novel lipid-lowering therapy targeting various cardiovascular diseases.
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer
Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer have been highlighted in this Industry Outlook article.
AstraZeneca buys licence for cholesterol treatment from China's CSPC
AstraZeneca PLC (LSE:AZN) shares got a small boost as the UK's largest pharma company snapped up a licence for a drug that could lower in the bloodstream, paying $100 million initially. The FTSE 1...
AstraZeneca to pay up to $2 billion to license cardiovascular drug
AstraZeneca on Monday said it will pay up to $2 billion to license a cardiovascular drug.
AstraZeneca in $1.9 bln licensing deal with HK-listed CSPC
AstraZeneca said on Monday it would pay up to $1.9 billion to CSPC Pharmaceutical Group Ltd in an exclusive license agreement to boost the Anglo-Swedish drugmaker's cardiovascular pipeline.
Avillion announces positive high-level results from Phase III BATURA trial with AstraZeneca's inhaled anti-inflammatory medication Airsupra in asth...
London, UK, 7 October 2024 – Avillion Life Sciences Ltd (“Avillion”) announces that the ongoing BATURA Phase IIIb trial evaluating AstraZeneca's Airsupra (albuterol/budesonide) in patients with int...
AstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded Use
The FDA grants priority review to AZN's sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in first-quarter 2025.
Owkin Announces Partnership with AstraZeneca to Develop an AI gBRCA Pre-Screen Solution for Breast Cancer
PARIS--(BUSINESS WIRE)--Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new partner...
AZN's Tagrisso Gets FDA Nod for Expanded Use in NSCLC
The FDA approves AstraZeneca's Tagrisso for treating unresectable, stage III EGFR-mutated non-small cell lung cancer.
AstraZeneca PLC (AZN) Annual Deutsche Bank Leveraged Finance Conference (Transcript)
AstraZeneca PLC (NASDAQ:AZN ) Deutsche Bank's Depositary Receipts Virtual Investor Conference September 24, 2024 11:30 AM ET Company Participants Elizabeth Walton - Director, Investor Relations Con...
CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease
If approved, AZN's Fasenra will be the second biologic approved in the European Union to treat eosinophilic granulomatosis with polyangiitis.
AstraZeneca's experimental cancer drug shows no significant improvement in overall survival
AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key Insights
The latest trading day saw Astrazeneca (AZN) settling at $78.38, representing a -0.66% change from its previous close.
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease
The FDA okays AstraZeneca's Fasenra for treating adults with eosinophilic granulomatosis with polyangiitis. This is the second approved indication for the drug.
Related Companies